QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NASDAQ:BEAM

Beam Therapeutics - BEAM Price Target & Analyst Ratings

$48.79
+2.82 (+6.13%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$46.60
$50.74
50-Day Range
$36.73
$46.82
52-Week Range
$27.77
$80.00
Volume
1.95 million shs
Average Volume
823,281 shs
Market Capitalization
$3.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.29

Beam Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$72.75
49.11% Upside
High Prediction$102.00
Average Prediction$72.75
Low Prediction$53.00
TypeCurrent
2/2/22 to 2/2/23
1 Month Ago
1/3/22 to 1/3/23
3 Months Ago
11/4/21 to 11/4/22
1 Year Ago
2/2/21 to 2/2/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$72.75$74.86$87.67$125.00
Predicted Upside49.11% Upside50.83% Upside50.80% Upside43.83% Upside
Get Beam Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.


BEAM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BEAM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Beam Therapeutics Stock vs. The Competition

TypeBeam TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.65
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside44.29% Upside1,296.91% Upside7.06% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/31/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$62.00+42.69%
1/23/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$81.00 ➝ $77.00+73.46%
12/20/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$61.00 ➝ $66.00+64.59%
12/13/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$62.00+39.95%
11/15/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$102.00+107.40%
11/8/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$65.00 ➝ $53.00+39.80%
8/10/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$38.00 ➝ $60.00-6.99%
8/1/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$100.00+69.95%
9/24/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$85.00 ➝ $120.00+24.20%
9/10/2021Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$150.00+37.35%
5/11/2021Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
5/3/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Perform$85.00+13.05%
2/16/2021Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$145.00+38.10%
1/29/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$38.00 ➝ $100.00+0.11%
8/12/2020William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Raju Prasad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
3/2/2020Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$32.00+42.29%
(Data available from 2/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BEAM Price Target - Frequently Asked Questions

What is Beam Therapeutics's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Beam Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 5 buy ratings for BEAM. The average twelve-month price prediction for Beam Therapeutics is $72.75 with a high price target of $102.00 and a low price target of $53.00. Learn more on BEAM's analyst rating history.

Do Wall Street analysts like Beam Therapeutics more than its competitors?

Analysts like Beam Therapeutics more than other Medical companies. The consensus rating for Beam Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how BEAM compares to other companies.

Is Beam Therapeutics being upgraded by Wall Street analysts?

Over the previous 90 days, Beam Therapeutics's stock had 1 upgrade by analysts.

Does Beam Therapeutics's stock price have much upside?

According to analysts, Beam Therapeutics's stock has a predicted upside of 52.37% based on their 12-month price targets.

What analysts cover Beam Therapeutics?

Beam Therapeutics has been rated by BMO Capital Markets, Cantor Fitzgerald, Citigroup, Credit Suisse Group, Guggenheim, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:BEAM) was last updated on 2/2/2023 by MarketBeat.com Staff